Medexus Pharmaceuticals Inc. (MDP.TO)
CAD 2.04
(-5.99%)
CAD 2.04
(-5.99%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 155.73 Million USD | -3.47% |
| 2022 | 161.32 Million USD | 15.88% |
| 2021 | 139.22 Million USD | -6.25% |
| 2020 | 148.51 Million USD | 20.93% |
| 2019 | 122.81 Million CAD | 44.47% |
| 2018 | 85 Million CAD | 1085.88% |
| 2017 | 7.16 Million CAD | 23.71% |
| 2016 | 5.79 Million CAD | -1.72% |
| 2015 | 5.89 Million CAD | -17.61% |
| 2014 | 7.15 Million CAD | -16.76% |
| 2013 | 8.59 Million CAD | 1490.28% |
| 2012 | 540.6 Thousand CAD | 23.38% |
| 2011 | 438.15 Thousand CAD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 147.26 Million USD | -5.44% |
| 2023 Q4 | 155.73 Million USD | -2.9% |
| 2023 Q1 | 166.87 Million USD | 3.44% |
| 2023 Q2 | 166.17 Million USD | -0.42% |
| 2023 Q3 | 160.37 Million USD | -3.49% |
| 2023 FY | 155.73 Million USD | -3.47% |
| 2022 Q1 | 136.39 Million USD | -2.03% |
| 2022 Q4 | 161.32 Million USD | 10.26% |
| 2022 Q3 | 146.32 Million USD | 2.82% |
| 2022 FY | 161.32 Million USD | 15.88% |
| 2022 Q2 | 142.3 Million USD | 4.33% |
| 2021 Q2 | 137.21 Million USD | -4.03% |
| 2021 Q4 | 139.22 Million USD | 0.79% |
| 2021 Q3 | 138.13 Million USD | 0.67% |
| 2021 Q1 | 142.97 Million USD | -3.73% |
| 2021 FY | 139.22 Million USD | -6.25% |
| 2020 Q2 | 121.58 Million CAD | -2.92% |
| 2020 FY | 148.51 Million USD | 20.93% |
| 2020 Q3 | 138.04 Million CAD | 13.54% |
| 2020 Q4 | 148.51 Million USD | 7.58% |
| 2020 Q1 | 125.24 Million CAD | 1.98% |
| 2019 Q4 | 122.81 Million CAD | 44.1% |
| 2019 FY | 122.81 Million CAD | 44.47% |
| 2019 Q3 | 85.22 Million CAD | -0.15% |
| 2019 Q1 | 87.3 Million CAD | 2.7% |
| 2019 Q2 | 85.34 Million CAD | -2.24% |
| 2018 Q1 | 6.88 Million CAD | -3.9% |
| 2018 Q4 | 85 Million CAD | 2.89% |
| 2018 FY | 85 Million CAD | 1085.88% |
| 2018 Q2 | 7.07 Million CAD | 2.63% |
| 2018 Q3 | 82.61 Million CAD | 1068.51% |
| 2017 FY | 7.16 Million CAD | 23.71% |
| 2017 Q1 | 9.02 Million CAD | 55.71% |
| 2017 Q4 | 7.16 Million CAD | -8.68% |
| 2017 Q3 | 7.84 Million CAD | -12.06% |
| 2017 Q2 | 8.92 Million CAD | -1.07% |
| 2016 Q3 | 6.31 Million CAD | -6.56% |
| 2016 FY | 5.79 Million CAD | -1.72% |
| 2016 Q2 | 6.76 Million CAD | -8.31% |
| 2016 Q4 | 5.79 Million CAD | -8.3% |
| 2016 Q1 | 7.37 Million CAD | 25.09% |
| 2015 Q2 | 5.19 Million CAD | -16.43% |
| 2015 Q1 | 6.22 Million CAD | -13.04% |
| 2015 FY | 5.89 Million CAD | -17.61% |
| 2015 Q4 | 5.89 Million CAD | 32.73% |
| 2015 Q3 | 4.44 Million CAD | -14.57% |
| 2014 Q3 | 4.43 Million CAD | -19.86% |
| 2014 Q2 | 5.53 Million CAD | -16.96% |
| 2014 FY | 7.15 Million CAD | -16.76% |
| 2014 Q1 | 6.66 Million CAD | 0.0% |
| 2014 Q4 | 7.15 Million CAD | 61.3% |
| 2013 Q1 | 483.62 Thousand CAD | -3.6% |
| 2013 Q2 | 459.82 Thousand CAD | -4.92% |
| 2013 Q3 | 7.75 Million CAD | 1587.61% |
| 2013 FY | 8.59 Million CAD | 1490.28% |
| 2012 Q1 | 535.57 Thousand CAD | -9.56% |
| 2012 Q2 | 551.07 Thousand CAD | 2.89% |
| 2012 FY | 540.6 Thousand CAD | 23.38% |
| 2012 Q4 | 501.67 Thousand CAD | -7.2% |
| 2012 Q3 | 540.6 Thousand CAD | -1.9% |
| 2011 FY | 438.15 Thousand CAD | 0.0% |
| 2011 Q3 | 438.15 Thousand CAD | 0.0% |
| 2011 Q4 | 592.16 Thousand CAD | 35.15% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Aurora Cannabis Inc. | 838.67 Million CAD | 81.431% |
| Avicanna Inc. | 21.97 Million CAD | -608.808% |
| Avant Brands Inc. | 82.55 Million CAD | -88.648% |
| Cardiol Therapeutics Inc. | 36.7 Million CAD | -324.335% |
| Crescita Therapeutics Inc. | 24.59 Million CAD | -533.112% |
| Knight Therapeutics Inc. | 945.49 Million CAD | 83.529% |
| MediPharm Labs Corp. | 63.93 Million CAD | -143.573% |
| OrganiGram Holdings Inc. | 298.45 Million CAD | 47.82% |
| Canopy Growth Corporation | 1.3 Billion CAD | 88.024% |
| Willow Biosciences Inc. | 6.67 Million CAD | -2233.778% |
| Auxly Cannabis Group Inc. | 261.9 Million CAD | 40.538% |